GURU.Markets stock price, segment price, and overall market index valuation
The company's share price CureVac N.V.
CureVac is a German biotech company working with mRNA technology. Its stock price is a story of high hopes during the COVID-19 pandemic and subsequent disappointment due to the failure of its vaccine. The chart reflects the company's efforts to find new applications for its platform.
Share prices of companies in the market segment - Pharma virus
CureVac is a German biotech company working with mRNA technology. Its business focuses on developing vaccines and therapeutics. We classify it as part of the Pharmavirus sector, and the chart below reflects the dynamics of this cutting-edge field of biotechnology.
Broad Market Index - GURU.Markets
CureVac is a German biotech company, a pioneer in mRNA technologies for vaccine and therapeutic drug development. It is a component of the GURU.Markets index. The chart below shows the US market. See how this European company's stock compares to the US market.
Change in the price of a company, segment, and market as a whole per day
CVAC - Daily change in the company's share price CureVac N.V.
The volatility of CureVac, a biotech company working with mRNA technology, reflects the sector's high risks. Change_co is an immediate reaction to news about clinical trials of vaccines and other drugs. This indicator forms the basis for analysis of the advanced biotech sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma virus
CureVac N.V. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with CVAC, a pioneer in mRNA technology, helps assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
CureVac is a German biotech company, a pioneer in mRNA technology. The vaccine sector is extremely volatile, and CureVac's story is a prime example. The chart below reflects the average fluctuations in this industry, providing context for the company's stock valuation.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization CureVac N.V.
CureVac, a pioneer in mRNA technology, has been actively investing in the development of a portfolio of oncology drugs and vaccines over the past year. Its year-over-year share price performance, shown in the chart, reflects the market's assessment of this long-term strategy.
Annual dynamics of market capitalization of the market segment - Pharma virus
CureVac N.V. is a biotech company pioneering the development of mRNA technologies. Following the failure of its first COVID-19 vaccine, its goal is to prove the potential of its platform in other areas. The chart below shows how the market views its scientific prospects and its competition with Moderna and BioNTech.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
CureVac, like other mRNA companies, is going through a difficult period post-pandemic. Its stock price reflects not economic cycles, but its struggle to find new products and regain investor confidence. This chart tells the story of how a biotech company adapts to life after one resounding success (or failure).
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization CureVac N.V.
The performance of biotech company CureVac depends on its mRNA platform. Monthly fluctuations on the chart reflect news about its vaccine clinical trials (including for COVID-19 and influenza), the success of which determines its ability to compete with giants like Moderna and BioNTech.
Monthly dynamics of market capitalization of the market segment - Pharma virus
CureVac is a biotech company specializing in mRNA technologies for vaccine and therapeutic development. Since the pandemic, the company has shifted its focus to new developments. The performance chart for the biotech sector focused on viral diseases will reveal how much investors continue to believe in the potential of mRNA platforms to address future medical challenges.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech companies, especially those involved in mRNA technologies, can exhibit extreme volatility unrelated to the market. The chart below shows the overall sentiment. Is CureVac moving in sync with it, or is news about its developments creating a completely independent story for the stock?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization CureVac N.V.
CureVac, a German biotech company specializing in mRNA technologies, is experiencing high volatility. Weekly stock performance is driven by news about clinical trials of its vaccines and therapeutics, as well as competition from BioNTech and Moderna.
Weekly dynamics of market capitalization of the market segment - Pharma virus
CureVac, like other mRNA companies, is part of the volatile biotech sector. This chart compares its performance with the industry, showing how much of its movements are driven by general biotech sentiment and how much by unique data from its clinical trials.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
CureVac is a German biotech company, a pioneer in mRNA technology. Its shares follow the rhythm of development news. The chart shows how CureVac's performance is unaffected by general market fluctuations, driven by its unique scientific and commercial news.
Market capitalization of the company, segment and market as a whole
CVAC - Market capitalization of the company CureVac N.V.
CureVac's market capitalization is another dramatic story in the world of mRNA vaccines. The chart of this German company, one of the pioneers of this technology, reflects its failure in the first wave of the COVID-19 vaccine race and subsequent struggles to find its footing. Its volatility chronicles the search for new applications for its platform in the treatment of infectious diseases and cancer.
CVAC - Share of the company's market capitalization CureVac N.V. within the market segment - Pharma virus
CureVac is a pioneering company in mRNA technology. Its market capitalization reflects both its early failures with its COVID-19 vaccine and the continued potential of its technology platform for future vaccines and drugs. The chart below shows how the market views its chances of a second wind in this revolutionary field of medicine.
Market capitalization of the market segment - Pharma virus
CureVac is a leading company in mRNA technology. The chart below shows the overall market capitalization of the entire biotech sector. Its dramatic rise and fall during the pandemic is a story of the high stakes and scientific competition in vaccine development.
Market capitalization of all companies included in a broad market index - GURU.Markets
CureVac is a pioneering company in mRNA technology. Its market capitalization chart tells a dramatic story of scientific ambition, competition in the vaccine race, and the search for new applications for its platform. Its volatility reflects all the risks and potential of cutting-edge science.
Book value capitalization of the company, segment and market as a whole
CVAC - Book value capitalization of the company CureVac N.V.
For CureVac, a pioneer in mRNA technology, book value is its production capacity and vast accumulated capital. The chart below is a history of its scientific ambitions. Its dynamics reflect both investments in plant construction and capital management following the surge during the pandemic.
CVAC - Share of the company's book capitalization CureVac N.V. within the market segment - Pharma virus
CureVac is a pioneer in mRNA technologies. Its strength lies in its scientific platform, but commercializing vaccines and drugs requires manufacturing capacity. The share chart shows how the company is investing in building its own physical facilities for producing next-generation drugs.
Market segment balance sheet capitalization - Pharma virus
CureVac is a pioneer in the development of mRNA technologies. Its value lies in its scientific platform, capable of rapidly developing vaccines and drugs. A chart of its book value shows that its assets are primarily intangible (patents, R&D), which is typical for biotech, where breakthrough technology is the primary asset.
Book value of all companies included in the broad market index - GURU.Markets
CureVac's book value is derived from its innovative mRNA platform and manufacturing capabilities. The company's assets include R&D centers and manufacturing facilities capable of rapidly producing mRNA vaccines and therapeutics. The chart shows the material investment in one of the most advanced technologies in modern biopharmaceuticals.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - CureVac N.V.
CureVac is a pioneer in mRNA technology. Its book value reflects its laboratory and manufacturing facilities. Its market capitalization, meanwhile, is a rollercoaster ride, dependent on the clinical trial results of its vaccines and therapeutics. It's a measure of the potential of its entire scientific platform.
Market to book capitalization ratio in a market segment - Pharma virus
CureVac N.V. is a German biotech company, a pioneer in mRNA technology. Its core value is its scientific platform, not its laboratories. The chart shows how market expectations for its future vaccines and drugs compare to its tangible assets. This reflects investor confidence in the potential of mRNA.
Market to book capitalization ratio for the market as a whole
CureVac is a pioneer in mRNA technology. The company's value depends almost entirely on the success of its platform for creating vaccines and therapeutics. The market evaluates the future potential of the technology, not the labs. The chart illustrates how far investor expectations can deviate market capitalization from the modest book value of its assets.
Debts of the company, segment and market as a whole
CVAC - Company debts CureVac N.V.
CureVac, a biotech company working with mRNA technologies, uses debt to fund its extensive research and development. This chart illustrates how it raises capital for clinical trials of vaccines and therapeutics. In this knowledge-intensive industry, debt is the bridge between scientific hypothesis and finished product.
Market segment debts - Pharma virus
CureVac is a biotech company specializing in mRNA technologies. Since the pandemic, interest in this field has been enormous, but research requires colossal investments. Debt can be a tool for funding the development of new vaccines and therapeutics. The chart shows how CureVac manages its capital in the mRNA technology race.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio CureVac N.V.
CureVac is a pioneer in the development of mRNA technologies for vaccines and therapeutics. This cutting-edge field of science requires massive, sustained, and risky investments in research. This chart shows the company's reliance on debt. Low debt is critical, as it allows it to continue development even after individual programs fail.
Market segment debt to market segment book capitalization - Pharma virus
CureVac is a German biotech company, a pioneer in mRNA technology. Despite the failure of its first COVID-19 vaccine, it continues to develop this cutting-edge field. The chart shows the overall debt burden in the pharmaceutical industry, helping to understand how CureVac is funding its expensive research after this setback.
Debt to book value of all companies in the market
CureVac, a pioneer in mRNA technology, operates at the cutting edge of science. This chart shows the overall market leverage, which is an indicator of investor risk appetite. For companies like CureVac, which have yet to achieve stable profitability, the availability of venture and equity capital is highly dependent on overall market sentiment.
P/E of the company, segment and market as a whole
P/E - CureVac N.V.
CureVac is a biotech company pioneering the development of messenger RNA (mRNA)-based therapeutics. This chart reflects investor confidence in the potential of this technology beyond COVID-19 vaccines. Its value shows how willing the market is to bet on future advances in treating cancer and other diseases using mRNA therapies, despite past setbacks.
P/E of the market segment - Pharma virus
CureVac is a biotech company working with mRNA technology. This chart shows the average price-to-earnings ratio for this cutting-edge industry. Comparing a company's price-to-earnings ratio to this metric helps understand how the market views its chances of success after the failure of its first vaccine, and whether it has more or less confidence in the potential of its mRNA platform than its competitors.
P/E of the market as a whole
CureVac is a pioneer in mRNA technology, developing vaccines and therapeutics. Despite the failure of its first-generation COVID vaccine, the company continues to develop its platform. This chart shows the overall risk appetite in biotech. It helps us understand whether the market believes in the long-term potential of CureVac's technology or whether its valuation is still under pressure from past failures.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company CureVac N.V.
CureVac is a biotech company pioneering the development of messenger RNA (mRNA)-based therapeutics. This chart shows investor expectations regarding the success of its technology platform in developing vaccines and therapeutics. The valuation depends on clinical trial results and the company's ability to compete with other mRNA companies.
%20P%2FE%20CureVac%20N.V.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-CureVac-N.V.&v=1772593104652 "Chart of the company's future (projected) P/E CureVac N.V.")
Future (projected) P/E of the market segment - Pharma virus
CureVac is a German biotech company specializing in mRNA technologies for vaccine and drug development. This chart compares CureVac's future profitability expectations with those of its industry. It shows how investors view its scientific platform following the failure of its first COVID-19 vaccine and whether they believe its current developments will be successful.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-virus&v=1772593104711 "Future (projected) P/E graph of the market segment - Pharma virus")
Future (projected) P/E of the market as a whole
CureVac is a biopharmaceutical company pioneering the use of mRNA technologies to create vaccines and therapeutics. The company's success depends on breakthroughs in research and the ability to fund expensive clinical trials. The overall market optimism shown by this chart is critical to attracting investment in such cutting-edge scientific platforms.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772593104746 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit CureVac N.V.
CureVac is a biotech company pioneering the use of messenger RNA (mRNA) to create vaccines and therapeutics. Its financial performance depends on the success of clinical trials and partnerships with major pharmaceutical companies. This chart depicts the innovator's financial journey, where massive investments in science precede potential revenue.
Profit of companies in the market segment - Pharma virus
CureVac is a pioneer in messenger RNA (mRNA) technology, developing vaccines and therapeutics. This chart, which shows the overall profitability of the biotech sector, demonstrates how one technology can change everything. CureVac's success in creating effective mRNA products could not only generate enormous revenue but also shape the future of the entire pharmaceutical industry.
Overall market profit
CureVac is a pioneer in mRNA technology. The company is developing vaccines and therapeutics based on this cutting-edge platform. Its future depends on success in clinical trials and the ability to commercialize its developments. CureVac is betting on a scientific revolution in medicine, not on the current economic situation.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company CureVac N.V.
CureVac is a German biotechnology company focused on mRNA technologies for the development of vaccines and therapeutics. The future revenue projections reflected here are dependent on the success of its clinical programs. Analysts' expectations are based on research data, partnerships, and the potential of the mRNA platform for drug discovery.
%20profit%20of%20the%20company%20CureVac%20N.V.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-CureVac-N.V.&v=1772593104989 "Graph of future (projected) profit of the company CureVac N.V.")
Future (predicted) profit of companies in the market segment - Pharma virus
CureVac is a biopharmaceutical company pioneering the use of mRNA technologies to develop vaccines and therapeutics. This chart shows revenue forecasts for the entire antiviral pharmaceutical segment. It allows one to assess how the company's technology, which competes with more established mRNA platforms, compares to overall expectations for this revolutionary field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-virus&v=1772593105050 "Graph of future (predicted) profits of companies in a market segment - Pharma virus")
Future (predicted) profit of the market as a whole
CureVac is a pioneer in the development of mRNA technologies for vaccines and therapeutics. The company's success depends on breakthroughs in its scientific platform and clinical trial results. General economic conditions, reflected in this chart, influence its success indirectly through the availability of capital and the willingness of governments and investors to fund cutting-edge medical research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772593105079 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - CureVac N.V.
CureVac N.V. is a German biotech company specializing in the development of mRNA-based drugs and vaccines. This chart, which correlates market capitalization with revenue (often from collaborations), is a measure of faith in its technology platform. It shows how the company's valuation fluctuates depending on news about clinical trials and the competitive environment.
P/S market segment - Pharma virus
CureVac is a pioneer in mRNA technology, developing a new generation of vaccines and therapeutics. The company uses mRNA to instruct the body to produce proteins to fight diseases. This chart shows how investors estimate revenue in the mRNA technology sector, demonstrating the level of expectations for CureVac's scientific platform and its broad potential applications.
P/S of the market as a whole
CureVac N.V. is a German biotechnology company pioneering the use of messenger RNA (mRNA) to create vaccines and therapeutics. The company's success depends on its technological platform. This chart helps understand how the market values companies at the cutting edge of science compared to the overall economy.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company CureVac N.V.
CureVac N.V. is a German biotechnology company specializing in the development of mRNA-based therapeutics. This chart illustrates how the market values the company based on its projected future revenue from vaccines and therapeutics. This value is heavily dependent on the success of clinical trials and the company's ability to compete in the rapidly evolving field of mRNA technologies.
%20P%2FS%20CureVac%20N.V.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-CureVac-N.V.&v=1772593105178 "The graph of the company's future (projected) P/S CureVac N.V.")
Future (projected) P/S of the market segment - Pharma virus
CureVac N.V. is a German biotechnology company specializing in the development of messenger RNA (mRNA)-based drugs and vaccines. This chart compares investor expectations for its future revenue with the sector. The valuation reflects investor opinion on the potential of its mRNA platform beyond COVID-19, including in oncology and preventative vaccines.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20virus&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-virus&v=1772593105196 "Future (projected) P/S market segment graph - Pharma virus")
Future (projected) P/S of the market as a whole
CureVac is a pioneer in mRNA technology, developing vaccines and therapeutics. Despite the failure of its first COVID-19 vaccine, the company continues its research. This graph of investor expectations reflects their belief in the long-term potential of the mRNA platform to revolutionize medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772593105237 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales CureVac N.V.
This chart reflects the commercial trajectory of CureVac, a pioneer in mRNA technology. The company's revenue is generated through partnerships and potential sales of future vaccines and therapeutics. Growth will depend on successful clinical trials and the ability to monetize its powerful scientific platform.
Sales of companies in the market segment - Pharma virus
CureVac is a pioneer in mRNA technology, developing vaccines and therapeutics. The company has over 20 years of experience in this cutting-edge field of biotechnology. This chart shows the total revenue of the entire mRNA therapeutics and vaccines market, illustrating the commercial potential of the revolutionary technology CureVac specializes in.
Overall market sales
CureVac N.V. is a biotechnology company specializing in mRNA technology for vaccines and therapeutics. Its success depends on the results of clinical trials and government contracts. The overall economic situation, shown in this chart, influences the amount of government funding for pandemic preparedness programs and the development of innovative medicine.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company CureVac N.V.
CureVac is a biotechnology company pioneering the use of mRNA technologies to create vaccines and therapeutics. Its future revenue depends on the success of its clinical programs and the commercialization of its mRNA products. This chart reflects analysts' long-term expectations for the potential of its technology platform in various areas of medicine.
%20sales%20of%20the%20company%20CureVac%20N.V.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-CureVac-N.V.&v=1772593105513 "Schedule of future (projected) sales of the company CureVac N.V.")
Future (projected) sales of companies in the market segment - Pharma virus
CureVac is a biopharmaceutical company specializing in mRNA technology. This forecast chart details the expected revenue from their vaccines and therapeutics in development. It shows how analysts assess the commercial potential of their mRNA platform in various medical fields after the COVID-19 pandemic.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-virus&v=1772593105531 "Schedule of future (projected) sales of companies in the market segment - Pharma virus")
Future (projected) sales of the market as a whole
This timetable, reflecting the willingness of investors and governments to fund healthcare innovation, is critical for CureVac. The biotech company, which works with mRNA technology, relies on contracts and partnerships to develop vaccines. A favorable economic environment facilitates the allocation of funds for cutting-edge research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772593105561 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality CureVac N.V.
CureVac is a pioneer in mRNA technology, developing vaccines and therapeutics. This chart reflects the biotech company's financial performance during the intensive research phase. Profitability is a long-term goal and depends entirely on the success of its clinical programs, regulatory approvals, and commercialization of its mRNA products.
Market segment marginality - Pharma virus
CureVac is a German biotechnology company and a pioneer in mRNA technology. Its profitability depends on the successful development and commercialization of vaccines and therapeutics based on its mRNA platform. This chart shows the average profitability in the pharmaceutical industry. It provides context for assessing the potential and risks associated with CureVac's cutting-edge technologies.
Market marginality as a whole
CureVac is a biotechnology company pioneering mRNA technologies for the development of vaccines and therapeutics. The company's success depends on scientific breakthroughs and the ability to commercialize its developments. This graph, reflecting the overall investment climate, impacts the availability of capital for long-term research and development in cutting-edge science.
Employees in the company, segment and market as a whole
Number of employees in the company CureVac N.V.
CureVac N.V. is a biotechnology company pioneering the use of mRNA technologies to create vaccines and therapeutics. This chart reflects the size of its research and production teams. The dynamics, particularly the rapid changes, illustrate how the company mobilizes resources during major projects, such as the COVID-19 vaccine, and adapts after their completion.
Share of the company's employees CureVac N.V. within the market segment - Pharma virus
CureVac is a pioneer in mRNA technology, developing vaccines and therapeutics. Its greatest asset is its world-class team of scientists. This chart shows CureVac's share of the total number of specialists working with mRNA, reflecting its deep scientific expertise and historic contribution to the development of one of the most advanced technologies in medicine.
Number of employees in the market segment - Pharma virus
CureVac N.V. is a global biopharmaceutical company, a pioneer in mRNA technologies, developing vaccines and therapeutics. This chart shows employment in the viral pharmaceuticals sector. The growing number of scientists in this field reflects the high relevance of the fight against infectious diseases and the enormous potential of the mRNA platform for the rapid development of new vaccines.
Number of employees in the market as a whole
CureVac is a biopharmaceutical company pioneering mRNA technology. Their focus is on developing vaccines and therapeutics. This general work schedule does not affect their operations. The growth of their team of scientists and technicians depends on progress in clinical trials and attracting funding for new ambitious projects.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company CureVac N.V. (CVAC)
CureVac is a pioneer in mRNA technology. Like other biotech companies, its value lies in its scientific platform and potential products. This chart shows how the market values its intellectual property. A small team of scientists can create technology worth billions, resulting in a very high valuation per employee.
%20of%20the%20company%20CureVac%20N.V.%20(CVAC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-CureVac-N.V.-CVAC&v=1772593105905 "Chart of market capitalization per employee (in thousands of dollars) of the company CureVac N.V. (CVAC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma virus
CureVac is a German biotech company, a pioneer in mRNA technology. Although their first-generation mRNA COVID vaccine was unsuccessful, the company continues development. Their value lies in their mRNA platform. This chart reflects how the market values their R&D potential.
%20by%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-virus&v=1772593105909 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma virus")
Market capitalization per employee (in thousands of dollars) for the overall market
CureVac is a pioneer in the development of mRNA technologies for vaccines and therapeutics. The company's market capitalization is based on the potential of its scientific platform. This metric demonstrates the enormous value per employee, as its small team of scientists possesses technology capable of rapidly creating new drugs against a wide range of diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772593105937 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company CureVac N.V. (CVAC)
CureVac is a pioneer in mRNA technology, the basis for COVID-19 vaccines. Like other biotech companies in the field, the company invests heavily in research. This chart shows not profit, but rather the amount of R&D investment per scientist working on the development and testing of new vaccines and therapeutics.
%20Chart%20CureVac%20N.V.%20(CVAC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-CureVac-N.V.-CVAC&v=1772593105977 "Company Profit Per Employee (in thousands of dollars) Chart CureVac N.V. (CVAC)")
Profit per employee (in thousands of dollars) in the market segment - Pharma virus
CureVac is a clinical-stage biotech company, a pioneer in mRNA technologies (a competitor of Moderna). This chart shows the benchmark for the biotech sector. In this industry, the average profit per employee is typically deeply negative. The benchmark is determined not by profit, but by the burn rate of the R&D budget.
%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-virus&v=1772593106025 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma virus")
Profit per employee (in thousands of dollars) for the market as a whole
CureVac is a German biotech company, a pioneer in mRNA technology. They are developing mRNA vaccines (including for COVID-19) and drugs. This is one of the most advanced fields of science. This graph shows how a model where all value is created by the intellectual labor of a small group of biologists differs from the market in terms of personnel efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772593106045 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee CureVac N.V. (CVAC)
CureVac is a pioneer in mRNA technology, developing vaccines and therapeutics. Its revenue per employee is volatile and depends on partnerships and development stages. This chart shows revenue from collaborations with pharmaceutical giants, which fund the company's research until its products are brought to market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-CureVac-N.V.-CVAC&v=1772593106098 "Sales chart per company employee CureVac N.V. (CVAC)")
Sales per employee in the market segment - Pharma virus
CureVac is a biotech company, a pioneer in mRNA technology. They are developing vaccines (including for COVID-19) and drugs based on messenger RNA. It's an R&D-intensive business. This chart shows their stage of development. Revenue (if any) comes from partnerships, and the productivity of their research team is focused on creating future breakthrough drugs.
Sales per employee for the market as a whole
CureVac (CVAC) is a German biotech company, a pioneer in mRNA technology. They rose to prominence during the pandemic, although their COVID-19 vaccine was not as successful as their competitors'. They continue R&D. This chart for a biotech in the R&D phase shows inefficiencies in the traditional sense. Revenue from partnerships (if any) is divided by a large staff of high-priced scientists. This reflects intensive investment in the mRNA platform.
Short shares by company, segment and market as a whole
Shares shorted by company CureVac N.V. (CVAC)
CureVac is a German biotech company, a pioneer in mRNA technology. Despite the failure of its first COVID-19 vaccine, they continue to develop oncology and other vaccines. This chart shows strong bearish sentiment. Skeptics likely believe the company is hopelessly behind Moderna and BioNTech and doubt the success of their current developments, fearing further capital burn.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-CureVac-N.V.-CVAC&v=1772593106191 "Short Shares Chart for the Company CureVac N.V. (CVAC)")
Shares shorted by market segment - Pharma virus
CureVac (CVAC) is a German biotech company specializing in mRNA technology. They rose to prominence during the pandemic, but their COVID vaccine was late in coming. This chart shows bets against the viral pharma sector. Shorts in this segment reflect investor disillusionment with second-tier mRNA companies and doubts about their ability to bring new, successful products to market.
Shares shorted by the overall market
CureVac (CVAC) is a biotech (mRNA vaccines). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives CVAC of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator CureVac N.V. (CVAC)
CureVac is a German biotech company, a pioneer in mRNA technologies. The stock is highly volatile and dependent on R&D. A chart reading above 70 may reflect positive trial data or new partnerships. Oversold levels (<30) are often associated with research setbacks or general risk aversion in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-CureVac-N.V.-CVAC&v=1772593106342 "RSI 14 indicator chart for the company's stock CureVac N.V. (CVAC)")
RSI 14 Market Segment - Pharma virus
CureVac N.V. is a German biotech company specializing in mRNA technology. It develops vaccines (including for COVID-19) and therapeutics. This chart measures the collective momentum of the mRNA biotech sector. It clearly shows when the entire niche is overheated by expectations or oversold by setbacks.
RSI 14 for the overall market
CureVac (CVAC) is a biotech company developing mRNA technologies. This chart is its lifeline. During periods of euphoria (and pandemics), investors are willing to fund the "future of medicine." During moments of panic, the hype fades, and investors flee unprofitable R&D projects, demanding real profits, which CVAC lacks.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CVAC (CureVac N.V.)
CureVac (CVAC) is a German biotech company and a pioneer in mRNA technology (along with Moderna and BioNTech). The company is developing mRNA vaccines against infectious diseases (COVID-19, influenza) and oncology drugs. This chart shows the average target price, which reflects analysts' assessments of the potential of their mRNA platform and clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CVAC-CureVac-N.V.&v=1772593106648 "A chart showing analyst consensus forecasts for the expected stock price. CVAC (CureVac N.V.)")
The difference between the consensus estimate and the actual stock price CVAC (CureVac N.V.)
CureVac is a German biotech company, a pioneer in mRNA technology. Despite its COVID vaccine failure, it continues R&D in oncology and infectious diseases. This chart shows the difference between the consensus forecast and the price. It reflects whether analysts believe in the long-term potential of its scientific R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CVAC-CureVac-N.V.&v=1772593106737 "A chart showing the difference between the consensus forecast and the actual stock price. CVAC (CureVac N.V.)")
Analyst consensus forecast for stock prices by market segment - Pharma virus
CureVac is a German biotech company and a pioneer in mRNA technology. Following the failure of its first COVID vaccine, it is focusing on second-generation vaccines and oncology. This chart shows analysts' overall expectations for the pharmaceutical sector. It reflects whether experts believe the company can recover and catch up with the leaders (Moderna, BioNTech).
Analysts' consensus forecast for the overall market share price
CureVac is a European biotech company, a pioneer in mRNA technologies (a competitor to Moderna). This is a risky R&D story. This chart of overall market sentiment is important. Optimism = the market is willing to burn money funding unprofitable biotechs with revolutionary potential. Pessimism = risk aversion, and capital for R&D dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index CureVac N.V.
CureVac is a German biotech company, a pioneer in mRNA technology. Despite the failure of their first COVID vaccine, they continue to develop mRNA therapeutics for cancer and other infections. This chart evaluates their second-generation R&D platform. It reflects the market's confidence in their technology and their ability to create a successful product post-COVID.
AKIMA Market Segment Index - Pharma virus
CureVac (CVAC) is a German pioneer in mRNA technologies (like BioNTech), which (despite its failure in the COVID vaccine race) continues to develop its R&D platform to create new vaccines and cancer drugs. This aggregate metric evaluates R&D companies. The graph shows the average value for the segment. This benchmark: how does this technology platform (CVAC) differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
CureVac is a German biotech company, a pioneer in mRNA technology, developing vaccines and cancer treatments. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific enterprise, which is striving to prove the effectiveness of its platform after the pandemic, compares to overall economic trends.
